() Noroclav Tablets for Dogs and Cats | Norbrook Laboratories

Noroclav Tablets

Noroclav Tablets for Dogs and Cats contain amoxycillin and clavulanic acid and are used for the treatment of skin infections (including superficial and deep pyodermas), urinary tract infections, respiratory infections, enteritis caused by bacteria susceptible to the active ingredients.

Target Species: Dogs and cats

  • Active Ingredient

    Noroclav 50 mg Tablets for Dogs and Cats Per tablet: Amoxicillin (as amoxicillin trihydrate) 40 mg Clavulanic acid (as Potassium clavulanate) 10 mg. Noroclav 250 mg Tablets for Dogs Per tablet: Amoxicillin (as amoxicillin trihydrate) 200 mg Clavulanic acid (as Potassium clavulanate) 50mg. Noroclav 500 mg Tablets for Dogs Per tablet: Amoxicillin (as amoxicillin trihydrate) 400 mg Clavulanic acid (as Potassium clavulanate) 100mg

  • Pharmaceutical Form

    Noroclav 50 mg Tablets for Dogs and Cats: Round pink biconvex tablet with a score line and 50 embossed on opposing faces. Noroclav 250 mg Tablets for Dogs: Round pink biconvex tablet with a score line and 250 embossed on opposing faces. Noroclav 500 mg Tablets for Dogs: Round pink biconvex tablet with a score line and 500 embossed on opposing faces. Tablets can be divided into equal halves.

  • Indications

    Treatment of the following infections caused by beta-lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid: - Skin infections (including superficial and deep pyodermas) caused by susceptible Staphylococci. - Urinary tract infections caused by susceptible Staphylococci or Escherichia coli. - Respiratory infections caused by susceptible Staphylococci. - Enteritis caused by susceptible Escherichia coli. It is recommended to carry out suitable tests for sensitivity testing when initiating the treatment. The treatment should only proceed if sensitivity is proven to the combination.

  • Dosage

    Administration is via the oral route. The dosage rate is 12.5 mg combined actives/kg bodyweight twice daily. The tablets may be crushed and added to a little food. Duration of therapy: Routine cases involving all indications: 5 to 7 days of treatment. If no improvement is observed after 5 to 7 days, the diagnosis should be re-assessed. Chronic or refractory cases: In these cases where there is considerable tissue damage, a longer course of therapy may be required so that it allows sufficient time for damaged tissue to repair. If no improvement is observed after two weeks, the diagnosis should be re-assessed.

Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region or visit the local government agency website for the most up to date information. Please see our terms and conditions for further information.

Prefer to speak directly to a member of our team?

Norbrook MENA 

All enquiries for the MENA team are manged by the Norbrook Head Office in Northern Ireland 

We are open Mon - Fri 9:00am - 5:00pm